Artelo Biosciences Reports Increased Net Loss and Improved Financial Position in Latest 10-Q Filing

Artelo Biosciences, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending March 31, 2026. The company recorded a net loss of $2.96 million, an increase from the $2.37 million loss reported in the same period last year. Total operating expenses rose to $2.69 million, compared to $2.38 million in the prior year, driven primarily by increased general and administrative costs, which surged to $1.92 million from $995,000. Research and development expenses decreased to $773,000 from $1.38 million, reflecting a strategic shift in resource allocation.

The company’s financial position improved markedly, with total assets increasing to $12.52 million as of March 31, 2026, up from $2.80 million at the end of 2025. This growth was largely attributed to a substantial increase in cash and cash equivalents, which rose to $10.27 million from $600,000. The increase in cash was primarily due to a successful private placement offering that generated approximately $10.03 million in net proceeds, aimed at supporting working capital and general corporate purposes.

In terms of operational metrics, Artelo's total liabilities also increased to $5.85 million from $4.07 million, largely due to higher accounts payable and accrued liabilities. The company’s stockholders’ equity turned positive, reaching $6.67 million compared to a deficit of $1.27 million at the end of 2025. The number of common shares outstanding increased to 876,032 from 673,008, reflecting the issuance of new shares as part of the recent financing activities.

Strategically, Artelo has been active in enhancing its capital structure. In March 2026, the company entered into a securities purchase agreement to issue common stock and warrants, which closed on March 30, 2026. This move is part of a broader strategy to raise funds for ongoing research and development activities. The company also filed a new shelf registration statement in May 2026, allowing it to raise additional capital over the next three years, contingent on market conditions.

Looking ahead, Artelo Biosciences acknowledges the ongoing challenges posed by global economic conditions, including inflation and market volatility, which may impact its operations and funding strategies. The company continues to monitor these factors closely while focusing on advancing its clinical-stage biopharmaceutical initiatives. Despite the current losses, Artelo remains committed to its long-term goals of developing therapeutics targeting lipid-signaling pathways and the endocannabinoid system.